| Literature DB >> 30805642 |
Zachary Miklja1, Amy Pasternak2, Stefanie Stallard1, Theodore Nicolaides3, Cassie Kline-Nunnally4, Bonnie Cole5, Rameen Beroukhim6, Pratiti Bandopadhayay6, Susan Chi6, Shakti H Ramkissoon7,8, Brendan Mullan1, Amy K Bruzek1, Angela Gauthier9, Taylor Garcia1, Christie Atchison1, Bernard Marini2, Maryam Fouladi10, D William Parsons11, Sarah Leary5, Sabine Mueller4, Keith L Ligon12, Carl Koschmann1.
Abstract
As the field of neuro-oncology makes headway in uncovering the key oncogenic drivers in pediatric glioma, the role of precision diagnostics and therapies continues to rapidly evolve with important implications for the standard of care for clinical management of these patients. Four studies at major academic centers were published in the last year outlining the clinically integrated molecular profiling and targeting of pediatric brain tumors; all 4 demonstrated the feasibility and utility of incorporating sequencing into the care of children with brain tumors, in particular for children and young adults with glioma. Based on synthesis of the data from these studies and others, we provide consensus recommendations for the integration of precision diagnostics and therapeutics into the practice of pediatric neuro-oncology. Our primary consensus recommendation is that next-generation sequencing should be routinely included in the workup of most pediatric gliomas.Entities:
Keywords: high-grade glioma; low-grade glioma; next-generation sequencing; pediatric; precision medicine
Mesh:
Year: 2019 PMID: 30805642 PMCID: PMC6682212 DOI: 10.1093/neuonc/noz022
Source DB: PubMed Journal: Neuro Oncol ISSN: 1522-8517 Impact factor: 12.300